• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Safety

  • Print
  • Share
  • E-mail

Norvir (ritonavir) tablet and solution for oral use

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – April 2010

 

Summary View

 

DRUG INTERACTIONS

Established and Other Potentially Significant Drug Interactions

Table 5. Established and Other Potentially Significant Drug Interactions

  • Bosentan: addition of new dosing recommendations for  and  when prescribed for the treatment of pulmonary arterial hypertension.
  • Tadalafil: addition of new dosing recommendations for when prescribed for the treatment of pulmonary arterial hypertension.
  • Colchicine: The addition of new dosing recommendations when prescribed for the treatment of familial Mediterranean fever or gout.  The addition of new dosing recommendations when prescribed for the prophylaxis of gout. The recommendation that colchicine should not be coadministered with Norvir (ritonavir) in patients with hepatic or renal impairment.